The Clinical and Cost Effectiveness of Dasatinib Versus Nilotinib for The First and Second Line Treatment of People with Chronic Myeloid Leukaemia

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.201
https://www.valueinhealthjournal.com/article/S1098-3015(17)30535-1/fulltext
Title : The Clinical and Cost Effectiveness of Dasatinib Versus Nilotinib for The First and Second Line Treatment of People with Chronic Myeloid Leukaemia
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30535-1&doi=10.1016/j.jval.2017.08.201
First page : A433
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 182
Categories :
Tags :
Regions :
ViH Article Tags :